ALS patients face dilemma over drug’s $158K price tag: ‘I’m not going to spend all my money on this’
Amylyx Pharmaceuticals priced Relyvrio “way too high,” said one patient. “They could cut the price in half and still make a hefty profit.”
Amylyx Pharmaceuticals priced Relyvrio “way too high,” said one patient. “They could cut the price in half and still make a hefty profit.” Read More
